Company intelligence / Profile preview
Senex Biotechnology
Columbia, South Carolina, United Statessenexbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Senex Biotechnology is developing selective CDK8/19 inhibitors with their lead compound showing excellent in vivo potency. Their latest drug candidate was anticipated to enter clinical trials within a year as of the search results date.
- Therapeutic areas
- OncologyImmunologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Senex Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senex Biotechnology.